Dihydrofolate Reductase Inhibitor Antimalarial Drug Class List

Drugs in Drug Class: Dihydrofolate Reductase Inhibitor Antimalarial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tilde Sciences	DARAPRIM	pyrimethamine	TABLET;ORAL	008578-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Teva Pharms	PYRIMETHAMINE	pyrimethamine	TABLET;ORAL	215506-001	Aug 13, 2021	AB	RX	No	No
Sanaluz	PYRIMETHAMINE	pyrimethamine	TABLET;ORAL	207127-001	Feb 28, 2020	AB	RX	No	No
Aurobindo Pharma Ltd	PYRIMETHAMINE	pyrimethamine	TABLET;ORAL	216983-001	Oct 25, 2022	AB	RX	No	No

Market Dynamics and Patent Landscape for Dihydrofolate Reductase Inhibitor Antimalarial Drugs

Last updated: April 26, 2026

What defines the dihydrofolate reductase inhibitor (DHFR) antimalarial market?

Dihydrofolate reductase inhibitor antimalarials target folate metabolism in Plasmodium and include classic DHFR inhibitors (notably pyrimethamine) and DHFR-based combination regimens such as pyrimethamine + sulfadoxine (SP). The market is shaped by (1) guideline placement within malaria treatment algorithms, (2) resistance-driven product replacement, (3) procurement volumes anchored to public-sector endemic regions, and (4) the patent and lifecycle status of legacy molecules.

Core commercial products in scope

Drug (DHFR class)	Typical regimen role	Market relevance today	Key constraint
Pyrimethamine	DHFR inhibitor component; often in SP	Still present in some public procurement and seasonal use	Resistance is common; SP efficacy varies by region
Sulfadoxine + pyrimethamine (SP)	First-line or intermittent preventive therapy in defined geographies and policy eras	Major historical public-sector spend; use is now more selective	Drug resistance (SP) and policy shifts

Treatment and prevention placement drives demand

• Case management use has declined in many settings where artemisinin-based combinations (ACTs) dominate first-line therapy, with SP or pyrimethamine used mainly when guided by local resistance patterns and policy.
• Intermittent preventive therapy use depends on country malaria control strategies and resistance. Historical reliance on SP has been constrained by SP resistance and shifting WHO recommendations (see WHO updates in sources below).

How do resistance and guideline changes move the market?

Resistance and WHO policy changes directly determine whether DHFR-based therapies expand or contract in public procurement and treatment protocols.

Resistance dynamics

• SP resistance correlates with P. falciparum DHFR/DHPS resistance mutations, driving variable cure rates and prompting guideline revisions and country-by-country restriction.
• In practice, resistance determines whether SP remains usable for:
  • treatment in specific geographies, or
  • prevention/ITP programs.

Guideline and policy shifts

WHO guidance on malaria has moved toward ACT-based treatment and has recalibrated preventive therapy recommendations as SP resistance data accumulates.

Evidence anchors include:

• WHO’s malaria treatment policy and the continued centrality of ACTs in first-line therapy (WHO overview and treatment guidance) [1].
• WHO guidance on intermittent preventive therapy for malaria and the role of SP under resistance-aware program designs (WHO prevention guidance) [2].

Where does demand concentrate geographically?

The DHFR inhibitor market concentrates in endemic regions with procurement programs that historically used SP or pyrimethamine-containing regimens, especially where:

• SP remains effective enough under local resistance profiles, and
• SP is incorporated into national treatment or prevention programs.

Because DHFR inhibitors are largely mature/legacy, the market share is typically tied to:

• public tenders and donor-funded programs, and
• negotiated supply of WHO-listed or prequalified products.

What is the patent landscape for DHFR antimalarials?

The patent landscape for DHFR antimalarials is dominated by:

• legacy small-molecule patents for pyrimethamine and early combination formulations, which have largely expired in most jurisdictions, and
• secondary patents that may persist longer for specific formulations, fixed-dose combinations, or manufacturing improvements.

Patent posture: practical reality

For DHFR antimalarial actives (especially pyrimethamine and SP):

• The original active ingredient patent terms largely date back decades.
• Market access today is usually governed by:
  • regulatory status and bioequivalence,
  • protection of specific fixed-dose combination products in a given market (if any secondary patents remain),
  • local registrations and tender eligibility rather than active-ingredient exclusivity.

Implication for competitive strategy

With most active ingredient protection expired, differentiation tends to come from:

• supply reliability and pricing under tender conditions,
• formulation engineering for tablets/co-blister packs,
• stability and shelf-life enhancements that reduce logistics cost,
• regulatory and pharmacovigilance performance.

Which patents actually matter for incumbents and entrants today?

In mature DHFR antimalarial markets, the patents that most influence commercial decisions are the ones that still exist for:

1. Fixed-dose combination compositions (if protected in specific jurisdictions via formulation claims).
2. Manufacturing process improvements (less common but can survive longer for process-dependent claims).
3. Data exclusivity / regulatory data protection (jurisdiction-dependent; does not require patent claims but can block fast generic entry).

Because the underlying actives are mature, investors typically focus on:

• whether any enforceable, still-in-force secondary IP exists for a specific branded or tender-specific product,
• whether patent terms are offset by SPC-like mechanisms or local extensions (jurisdiction dependent),
• whether there are blocking patents at the formulation level.

How does IP interact with regulatory pathway and procurement?

DHFR antimalarials are typically manufactured and registered through abbreviated pathways once patents expire. In procurement-driven markets, the time to regulatory approval and tender qualification often dominates over the incremental value of new IP.

Regulatory and guideline pipeline effects

• WHO recommendations and country malaria program designs determine whether a supplier can sell meaningfully, regardless of patent status.
• Even when IP barriers are absent, procurement rules favor prequalified or guideline-aligned products, and high-reliability supply.

What does “freedom to operate” usually look like for DHFR antimalarial actives?

For pyrimethamine and SP:

• Freedom to operate is commonly achievable for generic manufacturers in major markets due to expiration of primary patents.
• The main remaining risk usually comes from:
  • specific formulation/process claims tied to a branded fixed-dose product, and
  • any active secondary patents still in force in a specific country.

This shifts the patent landscape from “active ingredient block” to “country-by-country product claim screening.”

What market levers can new entrants pull despite mature patents?

Even with weak or expired core IP, entrants can still win share by targeting commercial levers that procurement favors:

Lever	What changes winning economics	Typical entry tactic
Tender pricing	Price per dose under public tenders	Low-cost manufacturing, scale, long supply contracts
Supply continuity	Avoiding stockouts and schedule failures	Multi-site manufacturing and distribution planning
Product acceptability	Tablet size, dissolution, stability, packaging	Formulation work even for legacy actives
Regulatory speed	Time to registration and prequalification	Early dossier planning and QC system maturity
Policy fit	Remaining in-use in national guidelines	Monitoring WHO and national resistance guidance

How should R&D budgets be assessed in this class?

Given the mature nature of DHFR inhibitor antimalarials, R&D decisions should discount “new single molecule DHFR entry” and instead consider:

• whether there is a credible path to clinical advantage (resistance-resilient profile),
• whether a fixed-dose combination offers a differentiated regimen that is compatible with current policy,
• whether meaningful formulation improvements are likely to translate into better program outcomes.

In practice, most “value” moves to:

• combination strategy aligned to current resistance and treatment algorithms,
• and manufacturing/formulation execution for procurement realities.

What does the public policy trajectory imply for future DHFR share?

WHO guidance has progressively emphasized ACTs for treatment and resistance-aware strategies for prevention, which reduces the long-run ceiling for SP as a general-purpose therapy. That said, DHFR inhibitors still persist where:

• resistance remains manageable, or
• policy permits use in specific protocols.

As resistance continues evolving, the market is likely to remain:

• regionally segmented,
• program-dependent,
• and highly price-competitive.

Key Takeaways

• DHFR inhibitor antimalarials are a mature, policy- and resistance-driven segment. Demand moves with local SP resistance profiles and WHO-aligned treatment and prevention policies [1], [2].
• Pyrimethamine and SP face limited long-run growth in many regions as ACTs dominate case management and as prevention strategies tighten in response to SP resistance [1], [2].
• The patent landscape is dominated by legacy actives with largely expired primary rights. Business-relevant IP today usually concentrates in country-specific secondary patents tied to formulations/processes and in regulatory exclusivities rather than active-ingredient monopolies.
• Competitive advantage is usually commercial and regulatory, not molecular IP. Pricing, tender qualification, supply continuity, and formulation acceptability govern share.

---

FAQs

1) Are pyrimethamine and SP still guideline-relevant for malaria?

They remain relevant in defined contexts where local resistance and national policy support their use, including prevention frameworks historically built around SP in intermittent preventive therapy and certain treatment pathways depending on WHO guidance and resistance levels [1], [2].

2) What most limits SP and pyrimethamine demand?

P. falciparum resistance to DHFR/DHPS driven by established mutation patterns. As resistance increases, countries restrict use and shift to other regimens [2].

3) Where does IP protection tend to survive in this class?

Where it does, it is usually secondary: fixed-dose combination formulation claims, specific manufacturing processes, or jurisdiction-specific extensions. The active ingredient itself is generally mature and widely genericized.

4) What is the primary competitive differentiator now?

Tender price plus reliable supply and a product that meets program requirements (stability, dosing convenience, and regulatory standing). Molecular innovation is not the main driver in most geographies.

5) How should investors think about growth prospects?

Growth is most plausible via niche geographies or protocol-specific demand where SP remains policy-permitted and resistance is controlled. Broad global expansion is constrained by WHO treatment strategy and SP resistance evolution [1], [2].

---

References

[1] World Health Organization. Guidelines for malaria treatment. WHO.
[2] World Health Organization. Intermittent preventive treatment of malaria in pregnancy and in children: recommendations and guidance on SP use and resistance-aware policy. WHO.